Open for Rare
Open for Rare is a publicly-available web interface for accessing results of the "Leukodystrophy Cell Map".
THE LEUKODYSTROPHY CELL MAP
More than 300 million people worldwide suffer from a rare disease. In the USA, a disease is considered rare when it affects less than 200,000 persons, which is the case for more than 6000 diseases and conditions. In Canada, it is estimated that 1 out of 12 people have a rare disease, 50% being children, 30% of which will not live to see their 5th birthday. Patients often report seeing an average of 4 to 7 physicians before being diagnosed, a serious burden to our health care systems.
Approved treatments are available for only 5% of all rare diseases, but the quest for novel drugs has been relatively successful in the past years, more than half of the 59 new drugs approved by the FDA in 2018 being to treat rare diseases. Almost 80% of rare diseases have a genetic origin and previous work from our group and many others has shown that multiple genetic mutations that cause rare diseases act by impairing the interaction of the target gene product with its cognate cell's partners.
To improve our understanding of the mechanisms of rare disease onset/progression and accelerate drug and biomarker discovery, we launched the ambitious initiative to build a cell map consisting of the entire network of protein-protein interactions involving leukodystrophy-causing gene products as well as the effect of causative mutations on network architecture (here called Differential Interactomes; see below for details). Leukodystrophies form a group of neurodegenerative diseases affecting the white matter of the brain. This “Leukodystrophy Cell Map” is revealing the blueprint of the cell's machinery and mechanisms at the origin of this rare genetic disease.
This initiative also serves to stimulate collaborations between scientists involved in leukodystrophy research.
MAPPING DIFFERENTIAL INTERACTOMES
L’Institut de recherches cliniques de Montréal n’est pas responsable du contenu de ce site Web.
The Montreal Clinical Research Institute is not responsible for the content of this website.